Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

The use of artificial intelligence and machine learning has the potential to provide some key benefits; however, there are still significant barriers to the implementation of these advanced technologies.

Barriers to AI Adoption

Bio/pharma companies should be approaching their decarbonization journey as a strategic business move for the future as industry stakeholders are placing greater value on sustainability.

Strategic Decarbonization

Potential conflicts of interest with advisory group members have led to EMA’s impartiality coming into questioned for some marketing authorization decisions. 

Demanding Impartiality

The political landscapes of both the EU and UK are set to change after the latest elections, which could affect the bio/pharma industry.

Polling Change

Pharmaceutical company, Nanomerics, and several companies that work with the pharmaceutical industry have been recognized by King Charles III for business achievements.

Royal Recognition

A revised regulatory variation framework should make lifecycle management more efficient in Europe.  

Streamlining Variations

Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.  

Budget Benefit

The industry’s M&A activity is on the up and expected to continue to rise in 2024.

On the Up and Up

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

As innovation accelerates, pharmaceutical regulators continue their path of maintaining proportion, balance, and restraint. 

Moderating Innovation to Equipoise Risk

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

From the Editor